Impact of trastuzumab treatment beyond disease progression for advanced/metastatic breast cancer on survival - Results from a prospective, observational study in Germany

Breast

Volumn 23, Issue 5, 2014, Pages 603-608

  Jackisch, C ^a   Welslau, M ^b   Schoenegg, W ^b   Selbach, J ^b   Harich, H D ^c   Schroder J ^b   Schmidt, M ^d   Gohler T ^b   Eustermann, H ^e   Ringel, R ^b   Hinke, A ^e  

^a Klinikum Offenbach GmbH   (Germany)

^b Hof ^*  (Germany)

^c Johannes Gutenberg University ^*  (Germany)

^d JOHANNES GUTENBERG UNIVERSITY   (Germany)

^e WiSP Research Institute   (Germany)

Author keywords

Breast cancer; Trastuzumab; Treatment beyond progression

Indexed keywords

CAPECITABINE; DOCETAXEL; NAVELBINE; PACLITAXEL; TRASTUZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DRUG RESPONSE; GERMANY; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; TREATMENT DURATION; VISCERAL METASTASIS; BREAST NEOPLASMS; DISEASE COURSE; FEMALE; FOLLOW UP; MIDDLE AGED; MORTALITY; PATHOLOGY; SURVIVAL; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GERMANY; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84908152265     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2014.06.003     Document Type: Article

References (22)

1. Arnold D., Andre T., Bennouna J., Sastre J., Osterlund P.J., Greil R., et al. Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with BEV plus CT: results of a randomized phase III intergroup study (TML study). JClin Oncol 2012, 30. CRA3503.
2. Slamon D., Eiermann W., Robert N., Pienkowski T., Crown J., Martin M., et al. Adjuvant trastuzumab in HER2-positive breast cancer. NEngl J Med 2011, 365:1273-1283.
3. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., et al. Use of chemotherapy plus a monoclonal antibody against her2 for metastatic breast cancer that overexpresses HER2. NEngl J Med 2001, 344:783-792.
4. Pusztai L., Esteva F.J. Continued use of trastuzumab (herceptin) after progression on prior trastuzumab therapy in HER-2-positive metastatic breast cancer. Cancer Invest 2006, 24:187-191.
5. von Minckwitz G., du Bois A., Schmidt M., Maass N., Cufer T., de Jong F.E., et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German Breast Group 26/Breast International Group 03-05. JClin Oncol 2009, 27:1999-2006.
6. von Minckwitz G., Schwedler K., Schmidt M., Barinoff J., Mundhenke C., Cufer T., et al. Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer. Eur J Cancer 2011, 47:2273-2281.
7. Valabrega G., Aglietta M. Trastuzumab beyond disease progression: case closed?. JClin Oncol 2009, 27:e121-e122.
8. Pegram M., Liao J. Trastuzumab treatment in multiple lines: current data and future directions. Clin Breast Cancer 2012, 12:10-18.
9. Grothey A., Sugrue M.M., Purdie D.M., Dong W., Sargent D., Hedrick E., et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). JClin Oncol 2008, 26:5326-5334.
10. Extra J.-M., Antoine E.C., Vincent-Salomon A., Delozier T., Kerbrat P., Bethune-Volters A., et al. Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study. Oncologist 2010, 15:799-809.
11. Cox D.R. Regression models and life tables. JRoy Stat Soc (B) 1972, 34:187-202.
12. Pietras R.J., Pegram M.D., Finn R.S., Maneval D.A., Slamon D.J. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene 1998, 17:2235-2249.
13. Fujimoto-Ouchi K., Sekiguchi F., Mori K. Preclinical study of continuous administration of trastuzumab as combination therapy after disease progression with trastuzumab monotherapy. Proc Amer Assoc Cancer Res 2005, 46. abst 5062.
14. Uleer C., Yazdan-Pourfard J., Holland B., Karl-Friedrich B., Moisidis-Tesch C., von Minckwitz G. Long-term partial remission with capecitabine/trastuzumab in a patient with metastatic breast cancer following progression on trastuzumab alone. Breast Care 2012, 7:45-47.
15. Geyer C.E., Forster J., Lindquist D., Chan S., Romieu C.G., Pienkowski T., et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. NEngl J Med 2006, 355:2733-2743.
16. Blackwell K.L., Burstein H.J., Storniolo A.M., Rugo H.S., Sledge G., Aktan G., et al. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 study. JClin Oncol 2012, 30:2585-2592.
17. Rugo H.S., Kaufmann P.A., Ulcickas Yood M., Tripathy D., Kaufman P.A., Mayer M., et al. registHER: an observational cohort study of survival of patients with HER2-positive metastatic breast cancer and use of trastuzumab following progression. Cancer Res 2009, 69(Suppl.2):250s. (abstract 3142).
18. Campiglio M., Bufalino R., Sandri M., Ferri E., Aiello R.A., De Matteis A., et al. Increased overall survival independent of RECIST response in metastatic breast cancer patients continuing trastuzumab treatment: evidence from a retrospective study. Breast Cancer Res Treat 2011, 128:147-154.
19. Tripathy D., Slamon D.J., Cobleigh M., Arnold A., Saleh M., Mortimer J.E., et al. Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. JClin Oncol 2004, 22:1063-1070.
20. National Comprehensive Cancer Network (NCCN) clinical practice guidelines in oncology: breast cancer 2012, http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf.
21. National Institute for Health and Clinical Excellence (NICE) Guidance CG81 advanced breast cancer: full guideline February 2009, http://www.nice.org.uk/nicemedia/live/11778/43414/43414.pdf.
22. AGO guidelines for diagnosis and treatment of breast cancer October 2012, http://AGO_Mamma_2012.zip.